European projects on antimicrobial resistance and healthcare-associated infections

MEMBER STATES

Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)

• Joint Programming Initiative on Antimicrobial Resistance

• AMR Research Funding Dashboard

EUROPEAN COMMISSION

EU Health Programme 2008-2013

• IMPLEMENT – Implementing strategic bundles for infection prevention and management (07/03/2012 - 31/01/2013)

Directorate-General for Research and Innovation

• INNOVATIVE MEDICINES INITIATIVE (IMI) – NEW DRUGS FOR BAD BUGS (ND4BB) PROGRAMME
  Innovative Medicines Initiative (IMI) – New Drugs for Bad Bugs (Nd4bb) programme

• COMBACTE – Combatting bacterial resistance in Europe (01/01/2013 – 31/12/2019)

• COMBACTE-CARE – maximizing capacity to provide a highly efficient resource for the conduct of clinical studies (01/01/2013 – 31/12/2019)

• COMBACTE-MAGNET – To develop innovative approaches against Gram-negative bacteria (01/01/2013 – 31/12/2019)

• DRIVE-AB – Driving reinvestment in R&D and responsible antibiotic use (01/10/2014 – 30/09/2017)

• ENABLE – European Gram-negative antibacterial engine (01/02/2014 – 31/01/2020)

• TRANSLOCATION - identifying new ways of getting potential antibiotics into bacteria

• PEARS – Predicting the evolution of antibiotic resistance in Streptococcus pneumoniae (01/06/2015 — 01/06/2017)

• HORIZON 2020 (2014-2020)
  COMPARE – Collaborative management platform for detection and analyses of (re)-emerging and foodborne outbreaks in Europe (01/12/2014 – 01/12/2019)

• PoC-Cycle – Innovative molecular diagnostics point-of-care device for MRSA (01/01/2014 – 01/12/2014)

• LimitMDR – Utilizing evolutionary interactions to limit multidrug resistance (01/05/2015 – 01/05/2020)

• PEARS –Predicting the evolution of antibiotic resistance in Streptococcus pneumoniae (01/06/2015 – 01/06/2017)

• FRAMEWORK PROGRAMME FOR RESEARCH AND TECHNOLOGICAL DEVELOPMENT (FP7) (2007-2013)
  ANTIRESDEV – The effects of antibiotic administration on the emergence and persistence of antibiotic-resistant bacteria in humans and on the composition of the indigenous microbiotas at various body sites (01/11/ 2009 – 30/4/2013)

• AIDA - Preserving old antibiotics for the future : assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off-patent antibiotics (01/12/2011 - 30/11/2016)

• APRES - The appropriateness of prescribing antibiotics in primary health care in Europe with respect to antibiotic resistance (01/10/2009 - 31/03/2014)

• CONCORD – Control of community-acquired MRSA: Rationale and development of counteractions (01/01/2009 – 30/06/2012)

• DIVANTI – The dividing cell membrane: a promising target for novel antibiotics (01/08/2013 – 31/07/2017)

• EFFORT – Ecology from farm to fork of microbial drug resistance and transmission (01/12/2013 –30/11/2018)

• EVOLOME – Genetic and phenotypic precursors of antibiotic resistance in evolving bacterial populations: from single cell to population level analyses (01/11/2010 – 31/10/2015)

• INTOPSENS – A highly integrated optical sensor for point of care label free identification of pathogenic bacteria strains and their antibiotic resistance (01/09/2008 – 29/02/2012)

• MON4STRAT – Therapeutic beta-lactam monitoring for stratified treatment of hospital-acquired pneumonia, improved dose-dependent efficacy, decreased treatment duration, and prevention of emergence of resistance (01/02/2014 – 31/01/2018)

• NeoStrep - Development of Group B Streptococcal vaccine to alleviate emerging antibiotic resistance through elimination of current prophylactic antibiotic strategies in GBS prevention.(01/01/2009 - 31/12/2011)

• NAREB - Nanotherapeutics for antibiotic resistant emerging bacterial pathogens (01/02/2014-31/01/2018)

• NONANTIRES – Non-genetic mechanisms of intrinsic antimicrobial resistance (01/08/2013 – 31/07/2015)

• PBDR – The population biology of drug resistance: key principles for a more sustainable use of drugs (01/07/2011 – 30/06/2017)

• PILGRIM - Preventing community and nosocomial spread and infection with MRSA ST 398 - instruments for accelerated control and integrated risk management of antimicrobial resistance (01/01/2009 - 31/12/2011)

• PROHIBIT – Prevention of hospital infections by intervention and training (01/01/2010 – 30/06/2014)

• R-GNOSIS - Resistance in Gram-Negative Organisms: Studying Intervention Strategies (01/10/2011-30/09/2016)

• SATURN – Impact of specific antibiotic therapies on the prevalence of human host resistant bacteria (01/01/2010 – 31/12/2014)